E-resources
Peer reviewed
Open access
-
Cherney, Robert J; Anjanappa, Prakash; Selvakumar, Kumaravel; Batt, Douglas G; Brown, Gregory D; Rose, Anne V; Vuppugalla, Ragini; Chen, Jing; Pang, Jian; Xu, Songmei; Yarde, Melissa; Tebben, Andrew J; Paidi, Venkatram Reddy; Cvijic, Mary Ellen; Mathur, Arvind; Barrish, Joel C; Mandlekar, Sandhya; Zhao, Qihong; Carter, Percy H
ACS medicinal chemistry letters, 11/2021, Volume: 12, Issue: 11Journal Article
BMS-813160 (compound 3) was identified as a potent and selective CCR2/5 dual antagonist. Compound 3 displayed good permeability at pH = 7.4 in PAMPA experiments and demonstrated excellent human liver microsome stability. Pharmacokinetic studies established that 3 had excellent oral bioavailability and exhibited low clearance in dog and cyno. Compound 3 was also studied in the mouse thioglycollate-induced peritonitis model, which confirmed its ability to inhibit the migration of inflammatory monocytes and macrophages. As a result of this profile, compound 3 was selected as a clinical candidate.
